Cargando…
Qualitative Patient Interviews to Characterize the Human Burden of Advanced Basal Cell Carcinoma Following Hedgehog Pathway Inhibitor Treatment
INTRODUCTION: Evidence of patients’ experiences of living with advanced basal cell carcinoma (aBCC) are limited, particularly after hedgehog pathway inhibitor (HHI) treatment. We explored the burden of aBCC on symptoms and patients’ everyday lives post HHI treatment. METHODS: In-depth, semi-structur...
Autores principales: | Konidaris, Gerasimos, Rofail, Diana, Randall, Jason, LaFontaine, Patrick R., Chen, Chieh-I., Bury, Denise, Geiger, Ashley, Sasane, Medha, Symonds, Tara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366056/ https://www.ncbi.nlm.nih.gov/pubmed/37330458 http://dx.doi.org/10.1007/s13555-023-00945-9 |
Ejemplares similares
-
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma
por: Paul, Eleanor, et al.
Publicado: (2021) -
Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation
por: Cowey, Lance, et al.
Publicado: (2022) -
Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study
por: Gümüş, Mahmut, et al.
Publicado: (2022) -
Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
por: Vogt, Annika, et al.
Publicado: (2004) -
Qualitative interviews with adults with Classic Galactosemia and their caregivers: disease burden and challenges with daily living
por: Randall, Jason A., et al.
Publicado: (2022)